SAN DIEGO, CA / ACCESS CABLE / July 27, 2022 / Plandai Biotechnology, Inc. (“plandai” or the “Company“) announces the termination of its non-binding letter of intent dated May 23, 2022, with Ms. Jessie Chiang, Taiwan-exclusive, worldwide rights licensee of Blood Filtration System for Blood Reduction Puriblood leukocytes. As previously discussed in the May 23, 2022 Company, Press release, the Company and Ms. Chiang intended to complete due diligence to reach a definitive material agreement whereby Ms. Chiang, through entities she controls, would license the Company to the exclusive rights of Puriblood technology for North, Central and South America for a period of 30 years. Upon closing of the proposed transaction, Ms. Chiang would have acquired a majority interest in the Company and would have become a Director, President and Chief Executive Officer of the Company.
Plandai continues its evaluation of several potential strategic opportunities to add value to its shareholders. On June 20, 2022, the Company engaged Hudgens, CPA to perform an independent audit of its financial statements for the years ended June 30, 2022 and 2021. The Company intends to file a registration statement upon completion.
FONT: Plandai Biotechnology
See source version at access cable.com: